88P A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea

ConclusionThis study's clinical benefit and toxicity for mNSCLC were comparable to those of clinical trials, although population tended to be more heavily treated and have poorer performance status. A favorable outcome could be expected in patients accompanying irAE during immunotherapy and unfavorable in patients who got previous RT. Reimbursement's PD-L1 criteria might be rational according to this study but need further study and analysis.Legal entity responsible for the studyHIRA.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research